Loading
  • Cortisol Modulation
  • Stories
  • Careers
  • Contact
  • Home
  • About
    • Our Team
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Search
  • Menu Menu
  • Home
  • About
    • Teams
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Stories
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Privacy Notice
  • Terms of Use
  • Site Map

About jeremiah@devisedesigns.com

This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 151 entries already.

Entries by jeremiah@devisedesigns.com

Other

Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator.

Zalachoras et al. • 2013 • Proc Natl Acad Sci U S A. 2013;110(19):7910-7915.

September 18, 2018
Other

Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.

Lenze et al. • 2014 • Int J Geriatr Psychiatry. 2014;29(9):962-9.

September 18, 2018
Other

Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486).

van der Lely et al. • 1991 • Ann Intern Med. 1991;114(2):143-4.

September 18, 2018
Other

1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as potent GR antagonists with reduced hERG inhibition and an improved pharmacokinetic profile.

Hunt et al. • 2015 • Bioorg Med Chem Lett. 2015;25(24):5720-5.

September 18, 2018
Other

Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects.

Agrawal et al. • 2011 • Mol Pharmacol. 2011;80(3):389-99.

September 18, 2018
Other

Administration of a selective glucocorticoid antagonist attenuates electroconvulsive shock-induced retrograde amnesia.

Andrade et al. • 2012 • J Neural Transm (Vienna). 2012;119(3):337-44.

September 18, 2018
Neurology

Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).

Webster et al. • 2017 • Br J Pharmacol. 2017;174(5):396-408.

November 15, 2017
Oncology

High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer

Veneris et al • 2017 • Gynecol Oncol.

November 15, 2017
Hypercortisolism (Cushing syndrome)

Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone.

Yuen et al. • 2017 • J Endocr Soc. 2017;1(4):237-246.

October 15, 2017
Metabolism, Other

The role of glucocorticoid receptors in metabolic syndrome and psychiatric illness.

Moraitis et al. • 2017 • J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):114-120.

September 21, 2017
Page 13 of 16«‹1112131415›»

Categories

  • Endocrinology
  • Hypercortisolism (Cushing syndrome)
  • Metabolism
  • Neurology
  • Oncology
  • Other
  • Uncategorized

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube

Scroll to top